Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of a Physical and Respiratory Rehabilitation Program (COPERIA-REHAB) for Patients With Persistent COVID-19 (SARS-CoV-2).

NCT05629884 is registered in ClinicalTrials.gov with Fundacin Biomedica Galicia Sur as lead sponsor.

NCT NCT05629884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05629884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of a Physical and Respiratory Rehabilitation Program (COPERIA-REHAB) for Patients With Persistent COVID-19 (SARS-CoV-2).
Lead sponsor
Fundacin Biomedica Galicia Sur
Phase
Not applicable
Overall status
Unknown status
Start date
December 14, 2022
Completion date
November 14, 2023
Enrollment
56 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive dysfunction, covid-19 recurrent, fatigue, sars-cov-2 infection